2015 年抗髓鞘少突胶质细胞糖蛋白抗体相关疾病谱神经免疫疾病诊断标准在多发性硬化症患者中的应用。
Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders.
机构信息
Department of Neurology, Mayo Clinic, Rochester, Minnesota.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
出版信息
JAMA Neurol. 2020 Dec 1;77(12):1572-1575. doi: 10.1001/jamaneurol.2020.2743.
Abstract
This study evaluates the proportion of patients with myelin oligodendrocyte glycoprotein IgG–associated disorders who fulfill the seronegative neuromyelitis optica spectrum disorder criteria.
摘要
本研究评估了髓鞘少突胶质细胞糖蛋白 IgG 相关疾病患者符合血清阴性视神经脊髓炎谱系疾病标准的比例。
相似文献
1
Application of 2015 Seronegative Neuromyelitis Optica Spectrum Disorder Diagnostic Criteria for Patients With Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders.2015 年抗髓鞘少突胶质细胞糖蛋白抗体相关疾病谱神经免疫疾病诊断标准在多发性硬化症患者中的应用。
JAMA Neurol. 2020 Dec 1;77(12):1572-1575. doi: 10.1001/jamaneurol.2020.2743.
2
Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.视神经脊髓炎谱系疾病伴髓鞘少突胶质细胞糖蛋白或水通道蛋白-4 抗体：阿尔及利亚患者的临床和辅助检查特征。
J Neurol Sci. 2017 Oct 15;381:240-244. doi: 10.1016/j.jns.2017.08.3254. Epub 2017 Aug 31.
3
Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases.脑脊液中髓鞘少突胶质细胞糖蛋白抗体与血清阴性病例的相关性。
Neurology. 2019 Nov 12;93(20):e1867-e1872. doi: 10.1212/WNL.0000000000008479. Epub 2019 Oct 23.
4
Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis.当髓鞘少突胶质细胞糖蛋白 (MOG) 抗体病和水通道蛋白 4 (AQP4)-IgG 阳性视神经脊髓炎谱系疾病 (NMOSD) 与抗 N-甲基-D-天冬氨酸 (NMDA) 受体脑炎共存时的比较。
Mult Scler Relat Disord. 2018 Feb;20:144-152. doi: 10.1016/j.msard.2018.01.007. Epub 2018 Jan 31.
5
Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica.抗水通道蛋白 4 抗体阴性的儿童视神经脊髓炎中髓鞘少突胶质细胞糖蛋白抗体持续存在。
Mult Scler. 2013 Jul;19(8):1052-9. doi: 10.1177/1352458512470310. Epub 2012 Dec 20.
6
[Anti-MOG associated disease].[抗髓鞘少突胶质细胞糖蛋白相关疾病]
Rev Med Suisse. 2024 Apr 24;20(871):828-832. doi: 10.53738/REVMED.2024.20.871.828.
7
Brain and spinal cord lesion criteria distinguishes AQP4-positive neuromyelitis optica and MOG-positive disease from multiple sclerosis.脑和脊髓病变标准将 AQP4 阳性视神经脊髓炎和 MO G 阳性疾病与多发性硬化症区分开来。
Mult Scler Relat Disord. 2018 Oct;25:246-250. doi: 10.1016/j.msard.2018.08.008. Epub 2018 Aug 9.
8
Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.AQP4-IgG 阳性视神经脊髓炎谱系疾病（NMOSD）与 MO 抗原抗体相关疾病（MOGAD）的临床放射学对比研究：一项前瞻性观察研究及文献复习
J Neuroimmunol. 2021 Dec 15;361:577742. doi: 10.1016/j.jneuroim.2021.577742. Epub 2021 Oct 8.
9
Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.视神经脊髓炎谱系疾病中的髓鞘少突胶质细胞糖蛋白抗体。
Rev Neurol (Paris). 2018 Dec;174(10):675-679. doi: 10.1016/j.neurol.2018.01.378. Epub 2018 Oct 4.
10
The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.补体蛋白在区分 AQP4-IgG 阳性与 MOG-IgG 阳性视神经脊髓炎谱系疾病中的临床价值。
Mult Scler Relat Disord. 2019 Oct;35:1-4. doi: 10.1016/j.msard.2019.06.035. Epub 2019 Jun 29.
引用本文的文献
1
A roadmap to increasing access to AQP4-Ig testing for NMOSD: expert recommendations.改善视神经脊髓炎谱系障碍（NMOSD）患者获取水通道蛋白4抗体（AQP4-Ig）检测的途径路线图：专家建议
Arq Neuropsiquiatr. 2025 Feb;83(2):1-11. doi: 10.1055/s-0045-1801845. Epub 2025 Mar 19.
2
Diagnostic Utility of MOG Antibody Testing in Cerebrospinal Fluid.MOG 抗体检测在脑脊液中的诊断效用。
Ann Neurol. 2024 Jul;96(1):34-45. doi: 10.1002/ana.26931. Epub 2024 Apr 9.
3
Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders.NMOSD 和 MOGAD 诊治进展：中枢神经系统自身免疫性炎症性疾病的两面。
Neurol Clin. 2024 Feb;42(1):77-114. doi: 10.1016/j.ncl.2023.06.009. Epub 2023 Aug 7.
4
A retrospective study of myelin oligodendrocyte glycoprotein antibody-associated disease from a clinical laboratory perspective.从临床实验室角度对髓鞘少突胶质细胞糖蛋白抗体相关疾病的回顾性研究。
Front Neurol. 2023 Sep 12;14:1187824. doi: 10.3389/fneur.2023.1187824. eCollection 2023.
5
The State of the Art of Pediatric Multiple Sclerosis.小儿多发性硬化症的现状。
Int J Mol Sci. 2023 May 4;24(9):8251. doi: 10.3390/ijms24098251.
6
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）：临床与MRI特征、诊断及管理综述
Front Neurol. 2022 Jun 17;13:885218. doi: 10.3389/fneur.2022.885218. eCollection 2022.
7
Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.用于视神经脊髓炎谱系障碍（NMOSD）和髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）的非补体相关单克隆抗体疗法
Neurotherapeutics. 2022 Apr;19(3):808-822. doi: 10.1007/s13311-022-01206-x. Epub 2022 Mar 10.
8
Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders.基于水通道蛋白4-IgG活细胞检测在视神经脊髓炎谱系障碍中的诊断价值。
Mult Scler J Exp Transl Clin. 2021 Nov 26;7(4):20552173211052656. doi: 10.1177/20552173211052656. eCollection 2021 Oct.
9
Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.有望造福视神经脊髓炎谱系疾病患者——从发病机制到临床试验。
Nat Rev Neurol. 2021 Dec;17(12):759-773. doi: 10.1038/s41582-021-00568-8. Epub 2021 Oct 28.
10
Frequency of myelin oligodendrocyte glycoprotein antibodies in a large cohort of neurological patients.一大群神经疾病患者中髓鞘少突胶质细胞糖蛋白抗体的频率
Mult Scler J Exp Transl Clin. 2021 Jun 25;7(2):20552173211022767. doi: 10.1177/20552173211022767. eCollection 2021 Apr-Jun.
Zotero 插件